Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 5 Multiple Myeloma 4 Lymphoma 3 Lymphoma, Large-Cell, Anaplastic 2 Hematologic Neoplasms 2 Adenocarcinoma 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Adenocarcinoma Metastatic 1 Granuloma, Plasma Cell 1 Gallbladder Neoplasms 1 Endometrial Cancer Recurrent 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Adenocarcinoma of Lung 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡